Portfolio company Abscint SA was acquired by Curium.
Abscint is a clinical-stage radiopharmaceutical company focused on developing innovative diagnostic imaging agents for oncology, particularly targeting HER2 expression in breast and gastric cancers using advanced in vivo imaging diagnostics
Abscint is a clinical-stage radiopharmaceutical company focused on developing innovative diagnostic imaging agents for oncology, particularly targeting HER2 expression in breast and gastric cancers using advanced in vivo imaging diagnostics.